332 related articles for article (PubMed ID: 30499193)
1. Which approach is better in eliciting health state utilities from breast cancer patients? Evidence from mainland China.
Li S; Wang M; Liu L; Chen G
Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12965. PubMed ID: 30499193
[TBL] [Abstract][Full Text] [Related]
2. Validity and responsiveness of EQ-5D-5L and SF-6D in patients with health complaints attributed to their amalgam fillings: a prospective cohort study of patients undergoing amalgam removal.
Lamu AN; Björkman L; Hamre HJ; Alræk T; Musial F; Robberstad B
Health Qual Life Outcomes; 2021 Apr; 19(1):125. PubMed ID: 33865400
[TBL] [Abstract][Full Text] [Related]
3. EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis.
Barnett C; Bril V; Bayoumi AM
Eur J Neurol; 2019 Mar; 26(3):452-459. PubMed ID: 30315714
[TBL] [Abstract][Full Text] [Related]
4. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
[TBL] [Abstract][Full Text] [Related]
5. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
Liu T; Li S; Wang M; Sun Q; Chen G
Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of EQ-5D-3L, EQ-5D-5L, and SF-6D Utilities of Patients with Musculoskeletal Disorders of Different Severity: A Health-Related Quality of Life Approach.
Kontodimopoulos N; Stamatopoulou E; Gazi S; Moschou D; Krikelis M; Talias MA
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887861
[TBL] [Abstract][Full Text] [Related]
7. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
8. Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China.
Liu L; Li S; Zhao Y; Zhang J; Chen G
Qual Life Res; 2018 May; 27(5):1323-1333. PubMed ID: 29492743
[TBL] [Abstract][Full Text] [Related]
9. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
[TBL] [Abstract][Full Text] [Related]
10. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
[TBL] [Abstract][Full Text] [Related]
12. Comparison of EQ-5D-5L, VAS, and SF-6D in Thai Patients on Peritoneal Dialysis.
Thaweethamcharoen T; Noparatayaporn P; Sritippayawan S; Aiyasanon N
Value Health Reg Issues; 2019 May; 18():59-64. PubMed ID: 30502661
[TBL] [Abstract][Full Text] [Related]
13. Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary.
Nikl A; Janssen MF; Jenei B; Brodszky V; Rencz F
Pharmacoeconomics; 2024 May; 42(5):583-603. PubMed ID: 38416366
[TBL] [Abstract][Full Text] [Related]
14. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
Wong CKH; Lang BHH; Yu HMS; Lam CLK
Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
[TBL] [Abstract][Full Text] [Related]
15. Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.
Xie S; Wu J; Chen G
Eur J Health Econ; 2024 Feb; 25(1):7-19. PubMed ID: 36709458
[TBL] [Abstract][Full Text] [Related]
16. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
17. A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population.
Kangwanrattanakul K
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):765-774. PubMed ID: 32981380
[TBL] [Abstract][Full Text] [Related]
18. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D.
Shiroiwa T; Fukuda T; Ikeda S; Igarashi A; Noto S; Saito S; Shimozuma K
Qual Life Res; 2016 Mar; 25(3):707-19. PubMed ID: 26303761
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.
Xu RH; Dong D; Luo N; Wong EL; Wu Y; Yu S; Yang R; Liu J; Yuan H; Zhang S
Eur J Health Econ; 2021 Jun; 22(4):547-557. PubMed ID: 33761029
[TBL] [Abstract][Full Text] [Related]
20. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
Tramontano AC; Schrag DL; Malin JK; Miller MC; Weeks JC; Swan JS; McMahon PM
Med Decis Making; 2015 Apr; 35(3):371-87. PubMed ID: 25670839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]